Skip to main content
S&P 5007,811.54+0.59%DOW51,654.95+0.83%NASDAQ27,366.17+0.64%BTC$82,516.00+0.84%ETH$2,488.45+0.36%GOLD$4,220.30+1.52%OIL$91.66+0.19%
Smart Investors Daily
SID Premium
LG

NYSE · LGNYZ

Ligand Pharmaceuticals Incorporated

Healthcare · Medical - Pharmaceuticals

$0.04

Down-$0.01 (-17.78%)

Updated Oct 10, 2026, 7:03 PM

SID Score

4.5/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
885.69K
P/E ratio
99
Dividend yield
0.00%
52-week range
— – —
Volume
4.97K
Avg. volume
119.99K

Price performance · LGNYZ

LGNYZ price history

1M range · 0 trading sessions · Daily adjusted prices

LGNYZ does not have enough price history for the selected period.

Data unavailable

Market data is busy. Please try again shortly.

Latest LGNYZ news

The latest Smart Investors Daily articles mentioning LGNYZ.

Stock researchCompany · Overview

LGNYZ research

Overview

Company profile and research snapshot.

Company profile

LIGAND PHARMS GENERAL CVR

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
Buy
Average target
—
Implied upside
—
Analysts
13
LGNYZ recent ratings
DateFirmRatingTarget
Sep 25, 2026BarclaysOverweight—
Sep 24, 2026HC Wainwright & Co.Buy—
Sep 23, 2026CitigroupBuy—
Aug 14, 2026Leerink PartnersOutperform—
Aug 7, 2026RBC CapitalOutperform—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Sep 29, 2026

Is Ligand Pharmaceuticals (LGND) Below Fair Value As It Funds AvenCell?

Why the AvenCell financing matters for Ligand Pharmaceuticals Ligand Pharmaceuticals (LGND) has agreed to provide up to $47 million in funding to AvenCell Therapeutics, tying most of the capital to clinical milestones in AvenCell’s CAR-T therapy programs. The agreement extends Ligand’s royalty-focused approach, giving the business potential future royalty rights on AvenCell’s existing CAR-T pipeline and any later programs that emerge from the partnership. Recent trading has been strong for...

Yahoo · Sep 29, 2026

Ligand Pharmaceuticals (LGND) Stock May Be 27% Undervalued After A New Royalty Deal

Ligand Pharmaceuticals has delivered a very strong run in recent years, and the question now is whether the cash the business can generate is enough to support where the stock trades today. With a Discounted Cash Flow (DCF) view available, the focus naturally turns to how the current price lines up with the cash flows investors expect the company to produce over time. Over the past 3 years, Ligand Pharmaceuticals has returned about 430.8%, which puts a lot of weight on whether the cash flow...

Yahoo · Sep 29, 2026

Is Ligand Pharmaceuticals (LGND) Using AvenCell CAR-T Royalties To Redefine Its Cash-Flow Playbook?

Ligand Pharmaceuticals recently entered a US$47 million financing agreement with AvenCell Therapeutics, including up to US$6 million in Series C funding and as much as US$41 million tied to clinical milestones for AvenCell’s CAR-T therapy programs. The deal deepens Ligand’s royalty-focused model by adding potential royalty streams on AvenCell’s current and future pipeline, further broadening its portfolio of over 200 partnered assets following the XOMA Royalty acquisition. We’ll now examine...

Yahoo · Sep 27, 2026

Ligand (LGND)-AvenCell Deal: Most of the Funding Is Tied to Milestones

Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) is building a business model that differs from that of many drug developers. Rather than relying on internally operated drug development programs, the company funds third-party programs and acquires royalty interests in exchange for economic rights in those assets. That model allows it to generate royalties and other income when the […]

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By